New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - budesonide 3mg - modified release capsule - 3 mg - active: budesonide 3mg excipient: gelatin   ethylcellulose dispersion type b ink black 10a2 iron oxide black iron oxide red methacrylic acid copolymer polysorbate 80 purified talc sugar spheres titanium dioxide   triethyl citrate - indicated for the induction of remission in patients with mild to moderate crohn's disease affecting the ileum and/or the ascending colon.

United States - English - NLM (National Library of Medicine)

ritedose pharmaceuticals, llc - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - 1.1 maintenance treatment of asthma budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. limitations of use: - budesonide inhalation suspension is not indicated for the relief of acute bronchospasm. the use of budesonide inhalation suspension is contraindicated in the following conditions: - primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. - hypersensitivity to budesonide or any of the ingredients of budesonide inhalation suspension [see warnings and precautions (5.3), description (11), adverse reactions (6.2)] . 8.1 pregnancy risk summary there are no adequate well-controlled studies of budesonide inhalation suspension in pregnant women. however, there are published studies on the use of budesonide, the active ingredient in budesonide inhalation suspension, in pregnant women. in animal reproduction studies, budesonide, administered by the su

Israel - English - Ministry of Health

astrazeneca (israel) ltd - budesonide - powder for inhalation - budesonide 200 mcg/dose - budesonide - budesonide - bronchial asthma.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - budesonide - powder for inhalation - budesonide 100 mcg/dose - budesonide - budesonide - bronchial asthma.

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - budesonide - powder for inhalation - 400 microgram(s) - glucocorticoids; budesonide

Australia - English - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - desonide, quantity: 0.5 mg/g - lotion - excipient ingredients: light liquid paraffin; propylene glycol; sorbitan monostearate; stearyl alcohol; sodium lauryl sulfate; self-emulsifying glyceryl monostearate; cetyl alcohol; methyl hydroxybenzoate; edetate sodium; propyl hydroxybenzoate; sodium hydroxide; citric acid; purified water - desowen lotion 0.05% is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses for adults and children aged 2 years and older.

United States - English - NLM (National Library of Medicine)

cintex services, llc - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide gel, 0.05% is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. patients should be instructed to use desonide gel, 0.05% for the minimum amount of time as necessary to achieve the desired results because of the potential for desonide gel, 0.05% to suppress the hypothalamicpituitary-adrenal (hpa) axis [see warnings and precautions ( 5.1)]. treatment should not exceed 4 consecutive weeks [see dosage and administration ( 2)]. desonide gel, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, desonide gel, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some

United States - English - NLM (National Library of Medicine)

artesa labs, llc - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide gel, 0.05% is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. patients should be instructed to use desonide gel, 0.05% for the minimum amount of time as necessary to achieve the desired results because of the potential for desonide gel, 0.05% to suppress the hypothalamicpituitary-adrenal (hpa) axis [see warnings and precautions ( 5.1)]. treatment should not exceed 4 consecutive weeks [see dosage and administration ( 2)]. desonide gel, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, desonide gel, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some

United States - English - NLM (National Library of Medicine)

kmm pharmaceuticals, llc - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide gel, 0.05% is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. patients should be instructed to use desonide gel, 0.05% for the minimum amount of time as necessary to achieve the desired results because of the potential for desonide gel, 0.05% to suppress the hypothalamicpituitary-adrenal (hpa) axis [see warnings and precautions ( 5.1)]. treatment should not exceed 4 consecutive weeks [see dosage and administration ( 2)]. desonide gel, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, desonide gel, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some

United States - English - NLM (National Library of Medicine)

northstar rx llc - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. it should not be used for longer than two weeks unless directed by a physician. desonide cream, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.